A public registry of stalled academic assets and shelved company compounds
Thousands of promising cancer compounds sit unused in university freezers and company archives. A public catalogue of what exists, what is known and who to ask would let others pick them up.
A searchable registry where universities and companies list oncology assets that have stopped development (with mechanism, stage reached, available data, reason for stopping and licensing contact), coupled with a standard non-exclusive research licence and a small brokerage function to match assets with academic groups or non-profit developers. NCATS's discontinued assets programme and AstraZeneca's open innovation portal are partial precedents; the National Cancer Institute's NExT programme has taken up some shelved compounds. Most stopped programmes end for portfolio, not scientific, reasons, and their data are otherwise lost.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA repurposing label pathway with short exclusivity that non-profits can hold
Shares Automatic offer of shelved cancer assets to non-profits after two years, A non-profit pharmaceutical company for the cancers markets ignore.
- IdeaA global ledger of negative results and failed compounds with mandatory deposition
Shares Secrecy and intellectual property block collaboration, Failures are hidden.
- IdeaAn antitrust safe harbour for cross-company combination trials and data pooling
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaGovernment reinsurance for phase 2 failures of first-in-class cancer drugs
Shares A single oncology trial data trust with mandatory deposit within eighteen months, The valley of death between lab and product.
- IdeaA shared library of pooled control arms to shrink and speed future trials
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaPatient-held portable consent for reusing samples and data across studies
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA commons for leftover trial biospecimens with standard access for approved research
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA federated learning consortium of cancer centres that jointly own the models
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.